Injective sees a jump — What is fueling the token rise

Traders Union
All News
Crypto News
Injective surges 10.00% today to $3.32

Highlights

Injective’s market capitalization stands at approximately $335.41 million, with a 24-hour trading volume of $62.69 million, reflecting moderate liquidity levels.
The project remains focused on building a fully decentralized, community-operated exchange protocol to minimize centralized oversight and control.
INJ trades at $3.32, below all key moving averages (MA-20 $4.23, MA-50 $4.64, MA-200 $9.04), with strong bearish momentum and a projected range of $3.92–$4.09 in the next five days.

Decentralized protocol focus sustains market activity amid modest capitalization

Injective reported a market capitalization of approximately $335.41 million and posted a 24-hour trading volume of $62.69 million. The project continues to focus on developing a fully decentralized, community-operated exchange protocol without centralized oversight.

Anton Kharitonov, expert at Traders Union, points out the persistent technical weakness in INJ. He notes the price is suppressed under all key moving averages, with daily momentum indicators confirming the entrenched downtrend. Kharitonov also observes little evidence of renewed demand or confidence despite the recent 10% daily rally. The project’s focus on decentralization has yet to impact price action or generate positive sentiment among major traders. "Until INJ can break key resistance and reverse its oversold state, I see little reason to expect a lasting recovery," Kharitonov warns.

Viktoras Karapetjanc, expert at Traders Union, sees long-term opportunity in Injective’s focus on decentralization and its active community model. He highlights that robust trading volumes and solid capitalization show continued market engagement. Karapetjanc believes the platform’s unique protocol remains well-positioned for adoption as decentralized exchanges gain mainstream traction. "A short-term pullback is possible, but the bullish structure remains intact and further growth is expected as market confidence returns," Karapetjanc states.

Oversold momentum persists as intraday gains defy prevailing resistance

The current price of INJ ($3.32) is below the short-term (MA-20 at $4.23), medium-term (MA-50 at $4.64), and long-term (MA-200 at $9.04) moving averages, indicating persistent selling pressure across all timeframes. The Ichimoku cloud identifies dynamic resistance at $4.36 (Kijun), placing the price firmly under overhead resistance in both trend and momentum terms. Momentum indicators show weak conditions: daily MACD and ADX are both bearish, reinforcing the downtrend, yet oversold signals from RSI (23.72), Stoch RSI (0.00), and CCI (–152.95) highlight that INJ is deeply oversold. BBP also confirms the sellers’ dominance, with the awesome oscillator supporting the prevailing bearish sentiment. INJ has rallied 10% today to $3.32, opening just below the previous close ($2.99 vs. $3.02) with no significant gap, currently trading near the top of today’s range ($2.67–$3.39). Intraday volatility has been high, with a noticeable push toward session highs, though this contrasts sharply with the longer-term momentum, underscoring a divergence between today’s bounce and the underlying trend.

Previously it was reported that Injective is experiencing sustained bearish momentum, trading well below all major moving averages with momentum indicators such as MACD, ADX, and oscillators (RSI, CCI, Stochastic RSI) confirming deep oversold conditions. Immediate resistance remains at the Ichimoku Kijun, while the lack of support and ongoing seller dominance suggest continued downside pressure despite the possibility of brief counter-trend rallies.

Source of Data: INJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.